GlassScriptPhysician profile
Sheena Patel
NPI 1427715663
$2,018.00
in general payments reported to CMS, 2019-2025
42 companies · $816 in 2025
The $816 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $289 · 2023: $614 · 2024: $299 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $175.72 | 2023 | |
| Abbvie INC. | $154.69 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $141.30 | 2022-2023 | |
| Lundbeck LLC | $131.25 | 2022-2025 | Abilify Asimtufii, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129.23 | 2023-2025 | Caplyta |
| Janssen Biotech, INC. | $121.55 | 2025 | Erleada |
| Alkermes, INC. | $115.87 | 2024-2025 | Lybalvi, Aristada, Vivitrol |
| Neurocrine Biosciences, INC. | $71.72 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $71.37 | 2023-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $65.68 | 2025 | Austedo Xr |
| Lilly USA, LLC | $64.50 | 2022-2023 | Mounjaro |
| Phadia US INC. | $55.00 | 2022 | |
| Tris Pharma INC | $53.77 | 2024-2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $51.55 | 2024-2025 | Cobenfy |
| Bausch Health US, LLC | $45.08 | 2025 | Wellbutrin, Aplenzin |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheena Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.